McKesson saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 80 to 84.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks often have an 80 or better RS Rating in the early stages of their moves.
McKesson has risen more than 5% past a 632.59 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Earnings grew 64% last quarter, up from 4% in the prior report. Revenue also increased, from 18% to 19%. The company is expected to report its latest numbers on or around Aug. 6.
McKesson earns the No. 2 rank among its peers in the Medical-Wholesale Drugs industry group. is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
